Results 61 to 70 of about 38,433 (267)

Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly

open access: yeseJHaem, 2023
The treatment of splenic marginal zone lymphoma is debated: splenectomy (the old standard‐of‐care) is better than chemotherapy but maybe not better than rituximab‐containing treatment.
Henna‐Riikka Junlén   +8 more
doaj   +1 more source

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Marginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam

open access: yesSAGE Open Medicine
Objective: The prognostic factors of patients diagnosed with marginal zone B-cell lymphoma at the National Institute of Hematology and Blood Transfusion between January 2014 and January 2024 were analyzed.
Binh Duc Vu   +8 more
doaj   +1 more source

Primary Breast Lymphoma in a 30-Year-Old Female Patient: A MALT Lymphoma or Pediatric Nodal Marginal Zone Lymphoma? A Case Report and Literature Review

open access: yesКлиническая онкогематология
Primary lymphoma accounts for less than 0.5 % of all breast malignancies. One of the most ubiquitous diseases in this group is extranodal lymphoma of mucosa-associated marginal zone lymphoid tissue (MALT lymphoma).
Mariya Vladimirovna Melnikova   +1 more
doaj   +1 more source

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

open access: yesBritish Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack   +16 more
wiley   +1 more source

PD1hi cells associate with clusters of proliferating B-cells in marginal zone lymphoma

open access: yesDiagnostic Pathology, 2018
Background Abnormally sustained immune reactions drive B-cell proliferation in some cases of marginal zone lymphoma but the CD4+ T-cell subsets, which are likely to contribute to the B-cell responses in the tumour microenvironment, are not well ...
Katherine Wickenden   +6 more
doaj   +1 more source

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

open access: yesCancer Medicine, 2020
Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The clinical features, treatment, and prognosis are not well characterized. We performed a multicenter retrospective study of CNS MZL.
Andrew J. Sunderland   +12 more
doaj   +1 more source

Clinical relevance of silent red blood cell autoantibodies. [PDF]

open access: yes, 2017
.
Alessandri, C   +14 more
core   +1 more source

ACUTE-ONSET HEMOPTYSIS AND RIGHT HILAR MASS: A RARE CASE OF EXTRA NODAL MARGINAL ZONE LYMPHOMA [PDF]

open access: bronze, 2021
Samiksha Gupta   +4 more
openalex   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

open access: yes, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha   +161 more
core   +2 more sources

Home - About - Disclaimer - Privacy